Company Description
Investments
Graphical Analysis

General Information

Files

Gloucester Pharmaceuticals, Inc.

Cambridge, MA
http://www.gloucesterpharma.com

John McBride
Executive VP & COO
One Broadway 14th Floor
Cambridge, MA 2142
617-583-1300

Legal Counsel: Wilmer Cutler Pickering Hale and Dorr LLP

Develops and commercializes products for the treatment of cancer. The Company employs an in-licensing strategy to build a diversified product portfolio to address the unmet medical need in the management of cancer. The Company's first compound, FK228 a novel HDAC inhibitor is in phase 2 clinical trials for the treatment of cutaneous T-cell lymphoma, as well as other hematological and solid tumor cancers.

Geographic Region: New England

Industry Sector: Biotechnology

Current Tearsheet and Analytics
» Download PDF

Investors

CIBC Capital Partners	ProQuest Investments	Prospect Venture Partners (FKA: Prospect Management LLC)
Rho Ventures (AKA: RHO Management)	Undisclosed Non Venture Firm

Investments - Tabular Analysis

	05/02/2008	01/15/2008	09/06/2007	12/20/2006	04/11/2006	11/01/2005	10/14/2004
Round Number	7	6	5	4	3	2	1
Total Investment	41.83	11.00	4.00	17.41	7.46	1.69	29.00
Stage	Late Stage	Other	Other	Other	Expansion	Expansion	Early Stage
Investors	CIBC Capital Partners ProQuest Investments Prospect Venture Partners (FKA: Prospect Management LLC) Undisclosed Non Venture Firm	ProQuest Investments Prospect Venture Partners (FKA: Prospect Management LLC) Rho Ventures (AKA: RHO Management) Undisclosed Non Venture Firm Undisclosed Non Venture Firm	ProQuest Investments	CIBC Capital Partners ProQuest Investments Prospect Venture Partners (FKA: Prospect Management LLC) Rho Ventures (AKA: RHO Management)	CIBC Capital Partners ProQuest Investments Prospect Venture Partners (FKA: Prospect Management LLC) Rho Ventures (AKA: RHO Management)	ProQuest Investments	CIBC Capital Partners ProQuest Investments Prospect Venture Partners (FKA: Prospect Management LLC) Rho Ventures (AKA: RHO Management) Undisclosed Non Venture Firm

Deal Terms - Tabular Analysis

	04/29/2008
Post-Money Valuation (best-estimate based on regulatory filings)	$ 95,755,483 (© 2008 VC Experts.com, Inc.)
Round of Financing	Series C
	Natl: 20%	Reg: 21%
Type of Preferred Stock	Participating Preferred
	Natl: 68%	Reg: 58%
Capped Participating Preferred	Yes
	Natl: 34%	Reg: 35%
Liquidation Preference for the Current Round	Pari Passu
	Natl: 32%	Reg: 37%
Multiple of the Liquidation Preference: 1x; 2x; 3x; > 3x.	0 - 1x
	Natl: 92%	Reg: 94%
Round Direction	Flat Round
	Natl: 8%	Reg: 8%
Anti-Dilution Protection	Weighted Average
	Natl: 90%	Reg: 91%
Redemption at Investor's Option	No
	Natl: 41%	Reg: 17%
Pay-to-Play Penalties

Cumulative Dividends	No
	Natl: 64%	Reg: 48%
Reorganization or Recapitalization	No
	Natl: 93%	Reg: 94%

Last Updated: February 20, 2008

The PEDC Buzz

» Private Company Valuations: Greylock Partners

» 1st Half 2008 Venture Capital Terms Report

» Private Company Valuations: Financial Services

Other News

How Does KIT Work?

Each company tearsheet is divided into three tabs: Company Description, Investments, and Graphical Analysis. You can move between each tab by clicking on it at the top of the tearsheet.

Company Description

Here you will find such information as the company location and main executive, or point of contact. You will also receive a breakdown of the investments and investors. By clicking on an investor's name, you will be taken to a brief overview page of that investment firm.

General Information

Files

Gloucester Pharmaceuticals, Inc.

Investors

Investments - Tabular Analysis

Deal Terms - Tabular Analysis

Valuation Ticker

The PEDC Buzz

How Does KIT Work?

Register Now

The PEDC Buzz